Clinical Outcomes Improvement and Perioperative Management of Surgical Patients: Volume II

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "General Surgery".

Deadline for manuscript submissions: 24 October 2024 | Viewed by 756

Special Issue Editors


E-Mail
Guest Editor
Department of Surgery, University of Thessaly, Biopolis, 41 110 Larissa, Greece
Interests: pancreatic surgery; liver surgery; bariatric surgery; surgical oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The art and science of clinical outcome analysis, quality improvement, perioperative management of surgical patients and patient safety continue to evolve at an increasingly rapid pace. In fact, over the years, novel concepts have arisen (risk stratification, shared decision making, interdisciplinary meetings, prehabilitation, etc.), new initiatives have taken shape (e.g., state/nation-wide or international clinical databases), and new technologies and methods have been adopted across all surgical specialties (e.g., minimally invasive or robotic approaches).

In order to care for our patients, raise the standards of healthcare services, and be successful in today’s and tomorrow’s rapidly changing healthcare environment, understanding and evolving these topics represents an essential duty of all surgeons, physicians and professionals related to surgical patients. In this context, we call all surgeons, physicians and professionals from all associated disciplines involved in the perioperative pathway of surgical patients (surgeons, anesthesiologists, radiologists, intensivists, cardiologists, oncologists, pulmonologists, nurses, physiotherapists, nutritionists, etc.) to contribute to this Special Issue. Following the big success of the first volume of the Special Issue, we decided to launch a second volume to discuss a greater number of relevant topics. Our vision remains to provide the best currently available evidence in this field, thus providing all the necessary information to clinicians on core concepts in the perioperative management of surgical patients.

Dr. Dimitrios E. Magouliotis
Prof. Dr. Dimitris Zacharoulis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • clinical outcomes
  • surgery
  • quality
  • quality of life
  • quality improvement
  • postoperative
  • morbidity
  • postoperative care

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1202 KiB  
Article
Contemporary Use of Sodium Glucose Co-Transporter 2 Inhibitors in Hospitalized Heart Failure Patients: A “Real-World” Experience
by Andrew Xanthopoulos, Nikolaos Katsiadas, Grigorios Giamouzis, Kleoniki Vangelakou, Dimitris Balaskas, Michail Papamichalis, Angeliki Bourazana, Nikolaos Chrysakis, Sotirios Kiokas, Christos Kourek, Alexandros Briasoulis, Niki Skopeliti, Konstantinos P. Makaritsis, John Parissis, Ioannis Stefanidis, Dimitrios Magouliotis, Thanos Athanasiou, Filippos Triposkiadis and John Skoularigis
J. Clin. Med. 2024, 13(12), 3562; https://doi.org/10.3390/jcm13123562 - 18 Jun 2024
Viewed by 258
Abstract
Background/Objectives: The aim of this study was to examine the association between in-hospital initiation of sodium glucose co-transporter 2 inhibitors (SGLT2is) and outcomes in hospitalized heart failure (HHF) patients utilizing data from a Greek center. Methods: The present work was a [...] Read more.
Background/Objectives: The aim of this study was to examine the association between in-hospital initiation of sodium glucose co-transporter 2 inhibitors (SGLT2is) and outcomes in hospitalized heart failure (HHF) patients utilizing data from a Greek center. Methods: The present work was a single-center, retrospective, observational study of consecutive HF patients hospitalized in a tertiary center. The study endpoint was all-cause mortality or HF rehospitalization. Univariate and multivariate Cox proportional-hazard models were conducted to investigate the association between SGLT2i administration at discharge and the study endpoint. Results: Sample consisted of 171 patients, 55 of whom (32.2%) received SGLT2is at discharge. Overall, mean follow-up period was 6.1 months (SD = 4.8 months). Patients who received SGLT2is at discharge had a 43% lower probability of the study endpoint compared to those who did not receive SGLT2is at discharge (HR = 0.57; 95% CI: 0.36–0.91; p = 0.018). After adjusting for age, gender, smoking, hemoglobin (Hgb), use of SGLT2is at admission, use of Angiotensin-Converting Enzyme Inhibitors (ACEI-Is)/Angiotensin Receptor Blockers (ARBs) at discharge and Sacubitril/Valsartan at discharge, the aforementioned result remained significant (HR = 0.38; 95% CI: 0.19–0.73; p = 0.004). The 55 patients who received SGLT2is at discharge were propensity score matched with the 116 patients who did not receive SGLT2is at discharge. Receiving SGLT2is at discharge continued to be significantly associated with a lower probability of the study endpoint (HR= 0.43; 95% CI: 0.20–0.89; p = 0.024). Conclusions: Initiation of SGLT2is in HHF patients may be associated with better outcomes. Full article
Show Figures

Figure 1

Back to TopTop